Ozempic Breaks Up with Hims & Hers: The Fall of Fast-and-Loose GLP-1 Telehealth

It finally happened. Novo Nordisk — the pharmaceutical powerhouse behind Ozempic and Wegovy — just ended its relationship with Hims & Hers.

And if you’ve been watching the rise of quick-fix telehealth weight loss programs, you know this split was inevitable.

🚨 GLP-1s Aren’t Candy — They’re Powerful Medication

Let’s get real: GLP-1s like semaglutide and tirzepatide are game-changing tools in the treatment of obesity, diabetes, and even psychiatric comorbidities. But they’re not benign. They require careful prescribing, medical oversight, and long-term planning.

But that’s not what companies like Hims & Hers have built.

What they built was a high-speed telehealth funnel:

• A few clicks and automated forms,

• No labs,

• No nuanced patient history,

• No follow-up plan,…and then boom: your “doctor-prescribed” Ozempic or Wegovy lands at your door like a monthly subscription box.

What could go wrong?Turns out: a lot.

💥 Novo Just Said the Quiet Part Out Loud

Novo Nordisk didn’t drop a dramatic press release, but the decision to terminate its GLP-1 supply agreement with Hims & Hers was loud enough.

Behind the scenes, this was a reputation-saving maneuver.Even Big Pharma doesn’t want its name attached to the sloppy prescribing practices and dubious medical oversight that’s becoming the telehealth norm.

For context: Hims & Hers reportedly had no psychiatrist on staff. No infrastructure for psychiatric side effect monitoring. No coordinated plan for managing nausea, mood instability, thyroid issues, or long-term metabolic markers.

But plenty of sleek marketing, influencer partnerships, and before-and-after photos designed to go viral.

👀 Patients Are the Ones Paying the Price

Here’s what we’ve seen on the ground:

• Women showing up in psychiatric care with suicidal ideation triggered by GLP-1 side effects, having never been warned of that risk.

• Patients who’ve lost 40+ lbs in a matter of months — with zero nutritional guidance, no plan for maintenance, and no idea why they’re suddenly exhausted and malnourished.

• People being told to “just stop the meds” when they raise concerns — because the platform can’t offer real clinical support.

This is not a weight loss revolution. It’s a crisis of ethical care.

🔄 Why I Created Balance360

I didn’t launch Balance360 because I wanted to jump on the GLP-1 trend. I launched it because patients came back to me — confused, unsupported, and scared.

They’d already been prescribed semaglutide or tirzepatide through these platforms. They were experiencing side effects. They had no lab monitoring, no guidance on hormonal interactions, psychiatric symptoms, or nutritional shifts.

It became crystal clear:Patients deserve real care — not rapid-fire prescriptions from a faceless app.

So I built Balance360. A psychiatry + metabolic health practice designed for:

• Thoughtful prescribing

• Psychiatric oversight of GLP-1 use

• Nutrition and lifestyle coaching

• Regular labs and safety monitoring

• Long-term, sustainable health goals

Not weight loss at any cost.Not aesthetic medicine disguised as healthcare.Just actual medicine. Done right.

⚠️ What This Split Really Means

Novo Nordisk walking away from Hims & Hers isn’t a minor industry hiccup. It’s the beginning of a reckoning for telehealth GLP-1 startups that have prioritized speed and scale over patient safety.

If a company that manufactures the drug doesn’t trust you to prescribe it safely…Maybe you shouldn’t be prescribing it.

💬 Final Word

You deserve better than a checkbox form and a 90-second approval process. You deserve real medical care, thoughtful guidance, and a team that sees you as a whole person — not just a BMI.

That’s what we do at Balance360.And we’re just getting started.